Unii-7D0yb67S97
| 中文名称 | Unii-7D0yb67S97 |
|---|---|
| 中文同义词 | 化合物 T10218;阿巴西普 |
| 英文名称 | Unii-7D0yb67S97 |
| 英文同义词 | 1-25-Oncostatin m (human precursor) fusion protein with ctla-4 (antigen) (human) fusion protein with immunoglobulin G1 (human heavy chain fragment), bimol (146-146')-disulfide;Bms 188667;Bms-188667;Ctla4-ig;Unii-7D0yb67S97;CTLA4lg;Abatacept;Orencia |
| CAS号 | 332348-12-6 |
| 分子式 | |
| 分子量 | 0 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | Mol File |
| 结构式 |
Unii-7D0yb67S97 性质
| 储存条件 | Store at 4°C, do not freeze |
|---|---|
| 形态 | 液体 |
| 颜色 | 无色至浅黄 |
| 水溶解性 | Soluble in water |
Abatacept (CTLA4lg) 是一种可溶性融合蛋白，由人 CTLA4 的胞外结构域和人 IgG1 Fc 部分的片段 (铰链，CH2 和 3 结构域) 组成。Abatacept 是选择性 T 细胞共刺激调节剂，也是一种用于自身免疫性疾病的蛋白药物。
Abatacept reduces paw edema, and the SC Multiple-dose group shows significantly greater (t
obs
= 2.50) paw edema reduction compared with the IV dose group.
Abatacept exhibits linear PK across the studied doses. The NCA clearance (CL) is 20.8 mL/day/kg, volume (V
ss
) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.
Abatacept (oral; 10 mg/kg; every 2 days) reduces the proportion of activated T cells (CD44highCD62L–) and inhibits the up-regulation of ICOS and CD71 in homozygous DO11.10 RAG-2
–/–
BALB/c (H-2d/d) mice.
| Animal Model: | Male Lewis rats (6-9 weeks old) with weights of 150-175 g |
| Dosage: | 10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 |
| Administration: | IV or SC |
| Result: | Reduced paw edema, and the SC Multiple-dose group showed significantly greater (t obs = 2.50) paw edema reduction compared with the IV dose group. |
| Animal Model: | Male Lewis rats (6-9 weeks old) with weights of 150-175 g |
| Dosage: | 10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study) |
| Administration: | IV or SC |
| Result: | The NCA clearance (CL) is 20.8 mL/day/kg, volume (V ss ) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-108829 | Unii-7D0yb67S97 Abatacept | 332348-12-6 | 1mg | 4000元 |
| 2024/04/30 | HY-108829 | Unii-7D0yb67S97 Abatacept | 332348-12-6 | 5mg | 8200元 |